• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Phase 3 trials of Sunovion’s nebulized glycopyrrolate meet primary endpoints

Sunovion has announced that the GOLDEN-3 and GOLDEN-4 Phase 3 clinical trials of SUN-101 glycopyrrolate inhalation solution for the treatment of moderate-to-very severe COPD both met their primary endpoints. SUN-101, delivered via the PARI eFlow handheld nebulizer, demonstrated statistically significant improvement in FEV1 versus placebo after 12 weeks for both the 50 µg and 25 µg doses. Sunovion acquired SUN-101, previously known as EP-101, when it acquired Elevation Pharmaceuticals in 2012.

The 12-week Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) trials were conducted at multiple sites in the United States with patients at least 40 years old. GOLDEN-3 enrolled 653 patients at 45 sites; GOLDEN-4 enrolled 641 patients at 49 sites. Sunovion announced the initiation of the trials, along with GOLDEN-5, in February 2015.

Sunovion Executive VP and Chief Medical Officer Antony Loebel commented, “The results from the trials represent significant progress in our mission to deliver medicines to people with COPD. We look forward to filing an NDA and the possibility of making SUN-101/eFlow available for patients.”

The company said that it expects to submit an NDA for SUN-101/eFlow by the end of fiscal year 2016.

Read the Sunovion press release.

Share

published on April 27, 2016

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews